Protein levels of major pathogenic cytokines in psoriasis were significantly reduced during apremilast administration from a total of 129 patients, contrary to placebo, additionally revealing IL-17F levels as a putative predictor of PASI reduction [90]. Here, IL17F is linked to psoriasis.